RxDoctor Payments Data

Vivian Bilasano, MD

Internal Medicine · Miramar, FLNPI 1821002825

Payments from drug & device makers

$3,302in general payments, 2019–2025

Across 91 payments — averaging $36.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$506
  • Amgen$365
  • Johnson & Johnson$301
  • Lilly USA, LLC$218
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$202
  • plus $584 from 13 others

What the payments were for

  • Food & beverage$3,302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,302 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$151,355
Medicare patients
116
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate23$36,821
EliquisApixaban24$32,466
JardianceEmpagliflozin19$26,668
OzempicSemaglutide21$23,623
FarxigaDapagliflozin Propanediol20$20,728
Atorvastatin Calcium371$2,483
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,345
Sildenafil Citrate11$2,100
Wixela InhubFluticasone Propion/Salmeterol19$2,088
Losartan Potassium248$1,923
Rosuvastatin Calcium181$1,554
Nifedipine ErNifedipine51$1,410
Metformin Hcl247$1,171
Amlodipine Besylate227$1,162
Albuterol Sulfate HfaAlbuterol Sulfate33$1,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$32,46624 claims
Boehringer IngelheimJardiance$506$26,66819 claims
Novo NordiskOzempic$1,126$23,62321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miramar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →